rethinkPeptides Search
Menu
Study breakdown

Can Synthesis Impurities in Calcitonin Peptide Drugs Trigger Immune Reactions?

In VitroPreliminary evidence
The takeaway

Some impurities generated during salmon calcitonin peptide synthesis showed potential to bind immune molecules and stimulate T cells, posing immunogenicity risk.

T-cell stimulation detected

Certain synthesis byproducts of salmon calcitonin showed the ability to activate immune T cells in laboratory assays

What the researchers found

Certain synthesis-derived impurities of salmon calcitonin showed potential to bind HLA molecules and stimulate T cells, indicating immunogenicity risk that warrants monitoring.

Why it matters

As more peptide drugs shift from biological to chemical manufacturing, understanding whether new impurities can trigger immune reactions is essential for drug safety.

The numbers in context

Impurities included amino acid insertions, deletions, and side-chain modifications from the synthesis process.

How the study worked

Combined computational (in silico) prediction with in vitro HLA binding and T-cell stimulation assays to assess immunogenicity of peptide impurities.

Who was studied

In silico and in vitro immunogenicity assessment of peptide impurities

What this study cannot tell us

In silico and in vitro methods can predict immunogenicity risk but cannot confirm actual clinical immune reactions. In vivo validation would be needed.

How to read the evidence

Rated preliminary: combined computational and in vitro assessment identifying risk, but clinical significance needs in vivo confirmation.

When this study was published

Published in 2024. Timely as more peptide drugs (especially GLP-1 drugs) shift to chemical synthesis manufacturing.

The bigger picture

More peptide drugs are being manufactured by chemical synthesis instead of biological production. Understanding the immunogenicity risk of synthesis-related impurities is essential for ensuring generic and biosimilar peptide drug safety.

Questions still open

  • Should immunogenicity testing be mandatory for all chemically synthesized peptide drugs?
  • Do these impurities accumulate at clinically relevant levels?

Common questions

What are peptide drug impurities?
Manufacturing byproducts where amino acids are inserted, deleted, or modified, creating slightly different molecules from the intended drug.
Can impurities in peptide drugs cause allergic reactions?
This study shows some impurities can potentially activate immune cells. Whether this translates to clinical reactions needs further investigation.

Read the original research

Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods.

Frontiers in pharmacology, 15, 1363139

Citation

Roberts, Brian J; Mattei, Aimee E; Howard, Kristina E; Weaver, James L; Liu, Hao; Lelias, Sandra; Martin, William D; Verthelyi, Daniela; Pang, Eric; Edwards, Katie J; De Groot, Anne S. (2024). Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods.. Frontiers in pharmacology, 15, 1363139. https://doi.org/10.3389/fphar.2024.1363139